CervoMed is trading 6.86% down at $1.63 after October 29 results showed its 159-patient Phase 2b RewinD-LB trial did not confirm the earlier Phase 2a result on the primary CDR-SB measure in the full study population. - The stock had already closed at $1.75, down 20.81% for the session. - Results included more encouraging subgroup and imaging findings. - No after-hours volume information was provided.